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Abstract
Background: Prostaglandin analogs reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension; however, these medications may affect the ocular surface and elicit ocular discomfort when preserved
with benzalkonium chloride (BAK).
Methods: This was an open-label, single-arm study conducted in Latin America from February 2012 to May 2013.
Patients with open-angle glaucoma or ocular hypertension who were intolerant of latanoprost 0.005 % were
transitioned to receive once-daily BAK-free travoprost 0.004 % containing polyquaternium-1 (Travatan® preserved
with POLYQUAD® [PQ], Alcon Laboratories, Inc; Fort Worth, TX) for 12 weeks. Mean change in IOP from baseline
(primary efficacy endpoint) and the percentage of patients who achieved a target IOP of ≤18 mmHg were evaluated
at all on-therapy visits. Ocular hyperemia, patient preference, and self-projected adherence were assessed at week 12.
Adverse events (AEs) were monitored throughout the study.
Results: All enrolled patients were included in the analysis (n = 191); the majority of patients (90.6 %, n = 173/191)
completed the study. Mean (SD) patient age was 67.5 (11.3) years, and mean baseline IOP was 14.8 mmHg. Mean IOP
was reduced by 0.94 mmHg at week 6 and by 1.09 mmHg at week 12 (P < 0.001 for both). A greater percentage
of patients achieved a target IOP of ≤18 mmHg at week 6 (93.1 %; n = 163/175) and week 12 (93.3 %; n = 166/178)
compared with baseline (89.5 %; n = 171/191). There was a 10.5 % increase in the percentage of patients with “none/
trace” amounts of hyperemia. Most patients preferred the study medication (81.5 %; n = 141/173) and were confident
that they would adhere to their preferred medication (90.8 %; n = 157/173). No serious AEs were reported, and eye
irritation (3.7 %; n = 7/191) was the most common treatment-related AE.
Conclusions: Transitioning from BAK-containing latanoprost 0.005 % to BAK-free travoprost 0.004 % preserved with PQ
reduced IOP in patients with open-angle glaucoma or ocular hypertension who were intolerant of latanoprost. BAK-free
travoprost 0.004 % is a viable alternative for patients who require switching their IOP-lowering medications because of
tolerability issues.
Trial registration: ClinicalTrials.gov identifier, NCT01510145
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Background
Glaucoma is a progressive disorder characterized by op-
tical neuropathy that may lead to blindness [1]. It is the
second-leading cause of blindness worldwide, and in
Latin America as many as 13.6 million people are esti-
mated to be diagnosed with open-angle glaucoma by
2020 [2]. The disease may be especially burdensome in
the Latin America region because diagnosis and treat-
ment can be cost prohibitive [3]. Currently, the only
evidence-based treatment paradigm for glaucoma fo-
cuses on reducing intraocular pressure (IOP) [1], which,
if left untreated, has been associated with disease pro-
gression [4, 5].
The most commonly used IOP-reducing agents in
Latin America are β-blockers, which reduce aqueous
production [6], and prostaglandin analogs, which increase
uveoscleral and trabecular meshwork aqueous outflow [7,
8]. Although both agents effectively reduce IOP, a greater
reduction is typically obtained with prostaglandin analogs
[9]. In addition, β-blockers have been associated with sys-
temic cardiac and respiratory adverse effects, which may
limit their use in some patients [10–14]. All prostaglandin
analogs (eg, bimatoprost, latanoprost, and travoprost)
have a similar IOP-lowering efficacy (8.0 to 8.7 mmHg
from baseline) [15] of approximately 30 %, but they differ
in their incidences of hyperemia [16].
In a long-term study of patients with primary open-
angle glaucoma, travoprost 0.004 % preserved with ben-
zalkonium chloride (BAK) significantly decreased mean
24-h IOP from 23.4 mmHg at baseline to approxi-
mately 16.8 mmHg through 5 years of treatment; mean
IOP was reduced by approximately 28 % [17]. To improve
tolerability, a BAK–free formulation of travoprost 0.004 %
containing a polyquaternium-1 preservative has been de-
veloped. BAK is a quaternary ammonium compound
preservative [18] that has been associated with a variety
of adverse ocular symptoms (eg, burning/stinging,
hyperemia, foreign body sensation, reduced tear pro-
duction) [19–21] and detrimental effects on corneal
epithelium cell function [22–25]. POLYQUAD® (PQ) is
a BAK alternative used predominately in contact lens
solutions and artificial tears [23] and has been shown to
elicit fewer cytotoxic effects than BAK in vitro [23, 24].
Clinically, PQ-preserved ophthalmic solutions appear to
reduce ocular discomfort associated with drop administra-
tion without affecting efficacy [26, 27]. For example, PQ-
preserved travoprost 0.004 % was associated with a
slightly reduced incidence of eye irritation compared
with travoprost 0.004 % containing BAK while provid-
ing similar reductions in IOP [26]. However, the benefit
of switching patients who are intolerant of BAK-
preserved prostaglandin analogs such as latanoprost to
BAK-free formulations containing PQ has not been
thoroughly evaluated.
The purpose of the present study was to assess the effi-
cacy and tolerability of transitioning from BAK-containing
latanoprost 0.005 % to BAK-free travoprost 0.004 % con-
taining PQ in patients with open-angle glaucoma or ocu-
lar hypertension.
Methods
Study design and treatment
This 12-week, multicenter, open-label, single-arm study
(NCT01510145) was conducted in Argentina, Chile, and
Colombia from February 2012 to May 2013. Patients
with open-angle glaucoma or ocular hypertension who,
in the opinion of the investigator, would benefit from
discontinuation of latanoprost 0.005 % ophthalmic solu-
tion because of tolerability issues were transitioned to
receive BAK-free travoprost 0.004 % (Travatan® pre-
served with PQ; Alcon Laboratories, Inc., Fort Worth,
TX) once daily at approximately 8 PM for 12 weeks. The
study protocol was reviewed and approved by the follow-
ing independent review boards: Comité Independiente de
Ética para Ensayos en Farmacología Clinica (Buenos Aires,
Argentina), Comité Ético Científico del Servicio de Salud
Metropolitano Oriente (Santiago, Chile), Comité Ético de
la Fundación Oftalmológica Los Andes (Santiago, Chile),
Comité de Ética del Servicio del Salud Metripolitano Sur
Oriente (Santiago, Chile), Comité de Etica en Investiga-
ción del Hospital Clínico UC (Región Metropolitana,
Chile), Comité de Revisión de Estudios de Investigación
(Medellin, Colombia), and Clínica Oftalmológica del
Caribe (Barranquilla, Colombia). The study was per-
formed in accordance with ICH Good Clinical Practice
guidelines. All patients provided written informed con-
sent before initiation of study procedures.
Patients
Adult patients were allowed to participate if they were
diagnosed with ocular hypertension or open-angle glau-
coma in at least 1 eye, had been receiving latanoprost
0.005 % ophthalmic solution monotherapy (including
BAK-preserved generics) for ≥4 weeks before the screen-
ing visit, and would benefit from transitioning to BAK-
free travoprost. IOP must have been <30 mmHg in both
eyes while receiving latanoprost and had to pose no
threat to vision stability or the optic nerve. Best cor-
rected visual acuity was required to be >20/200 Snellen
(1.0 logMAR) in both eyes.
Women who were pregnant or lactating were not
allowed to participate. Patients were also excluded if
they had a history of allergy, hypersensitivity, or poor
tolerance to components of BAK-free travoprost con-
taining PQ; had any abnormality that precluded reliable
applanation tonometry; had corneal dystrophies, concur-
rent infectious or noninfectious conjunctivitis, keratitis,
uveitis, dry eye, keratoconjunctivitis sicca, or progressive
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retinal or optic nerve disease from any cause; had a his-
tory of or were at risk for uveitis or cystoid macular
edema; or had conventional or laser surgery in either
eye ≤3 months before screening. Patients who were re-
ceiving systemic medications that could affect IOP (eg,
oral β-adrenergic blockers, α-agonists and blockers,
angiotensin-converting enzyme inhibitors, and calcium
channel blockers) must have been on a stable dosage
for ≥7 days before screening.
Outcomes
Intraocular pressure was measured using Goldmann
applanation tonometry at screening and baseline and at
on-therapy visits at weeks 6 and 12; all on-therapy mea-
surements were obtained at approximately the same
time of day (±1 h) as baseline measurements. Change in
IOP from baseline to week 12 was the primary efficacy
endpoint; the percentage of patients who achieved a tar-
get IOP of ≤18 mmHg was also evaluated. Ocular
hyperemia was scored as 0 (“no hyperemia”) to 3 (“se-
vere hyperemia”) at baseline and week 12. Also at week
12, patients self-reported ocular discomfort on a scale
ranging from 0 (“no discomfort”) to 9 (“substantial dis-
comfort”). At the end of the study, patients were asked
to identify which medication they preferred: latanoprost
0.005 % or BAK-free travoprost 0.004 %. Based on their
medication preference, patients chose their level of con-
fidence (ie, “not at all confident,” “somewhat confident,”
or “very confident”) in answer to the question, “How
confident are you that you will use your glaucoma medi-
cation as prescribed, if your doctor prescribed (a) your
preferred medication, (b) your nonpreferred medication,
(c) medication that caused burning or stinging, and (d)
medication that did not cause burning or stinging?” Ad-
verse events (AEs) were collected at each study visit and
coded based on the Medical Dictionary for Regulatory
Activities (version 15.0).
Statistical analyses
The change in IOP from baseline to week 12 was ana-
lyzed using a mixed model including visit as a fixed ef-
fect and patient as a random effect. P values of <0.05
were considered statistically significant.
Results
Patients
A total of 191 patients were enrolled, received study
medication, and were included in the safety and full-
analysis datasets (ie, patients who received ≥1 dose of
study medication); 173 (90.6 %) patients completed the
study. Reasons for study discontinuation were AEs (n =
6), personal reasons (n = 6), loss to follow-up (n = 5), or
other reasons (n = 1). At baseline, patients had a mean
(range) age of 67.5 (23–89) years and were mostly white
(78.0 %; n = 149/191) and female (72.8 %; n = 139/191).
Efficacy
Mean IOP at baseline was 14.8 mmHg. Mean IOP de-
creased from baseline to week 12 by 1.09 mmHg (5.4 %;
P < 0.001; Fig. 1); a similar reduction in IOP was ob-
served at week 6 (0.94 mmHg; 4.7 %; P < 0.001). The per-
centage of patients achieving the target IOP of ≤18 mmHg
increased from 89.5 % (n = 171/191) at baseline to 93.1 %
(n = 163/175) at week 6 and 93.3 % (n = 166/178) at week
12. Mean ocular hyperemia score decreased from 0.94
at baseline to 0.74 at week 12. The percentage of pa-
tients with “none/trace” hyperemia increased from
26.7 % (n = 51/191) at baseline to 37.2 % (n = 64/172) at
study end (10.5 % increase; Fig. 2). Mean (SD) self-
assessed ocular discomfort score was 1.83 (2.33), which
was on the low end of the scale, and indicates minimal
Fig. 1 Intraocular pressure throughout the study. IOP = intraocular pressure. *P < 0.001
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discomfort levels. More patients preferred the study
medication over their prior medication (81.5 % [n =
141/173] vs 18.5 % [n = 32/173]) when given the choice
between them. Most patients were very confident that
they would use their preferred medication as prescribed
(preferred medication: 90.8 %, n = 157/173; nonpre-
ferred medication: 46.2 %, n = 80/173) and indicated a
high adherence level for medications free of local irrita-
tion effects (83.8 %, n = 145/173; Fig. 3).
Safety
Eight patients discontinued BAK-free travoprost because
of 9 AEs (ocular hyperemia, n = 3; eye irritation, n = 2;
conjunctival edema, n = 1; foreign body sensation in
eyes, n = 1; pingueculitis, n = 1; headache, n = 1). No ser-
ious AEs were reported. Forty-two AEs were reported by
29 patients (15.2 %; n = 29/191) during the study. The
most commonly reported AEs were eye irritation (3.7 %;
n = 7/191), eye pruritus (3.1 %; n = 6/191), and eye pain
(2.6 %; n = 5/191). Most AEs (83.3 %; n = 35/42) were
considered mild and related to treatment (Table 1). AEs
severe in intensity were reported in 4 patients and in-
cluded ocular hyperemia (n = 3), eye irritation (n = 1),
and conjunctival edema (n = 1).
Discussion
In this study, patients who transitioned because of intol-
erability from BAK-containing latanoprost to BAK-free
travoprost preserved with PQ had a reduction in IOP
after the switch. Additionally, patients reported fewer
ocular surface abnormalities and less hyperemia after
transitioning to the BAK-free medication. Few AEs were
reported and most were mild in severity.
Previous studies have demonstrated an approximately
1 mmHg reduction in IOP after transitioning from BAK-
containing latanoprost to BAK-free travoprost preserved
with sofZia® (Alcon Laboratories, Inc.) [28, 29]. In the
present study, a similar reduction of 1.09 mmHg in IOP
was observed after transitioning from BAK-containing
latanoprost to BAK-free travoprost preserved with PQ.
The reduction in IOP was observed by week 6 and was
maintained throughout the study, enabling more pa-
tients to reach the target IOP of ≤18 mmHg.
Ocular surface disease is prevalent among patients
with glaucoma, especially those who receive treatment
with ophthalmic solutions [30]. Although the exact mech-
anism for this remains unknown, BAK has been associated
with a variety of ocular symptoms such as burning, sting-
ing, foreign body sensation, and dry eye [19, 20, 30]. BAK
is a detergent used in ophthalmic solutions to prevent
microbial growth and perpetuate medication distribu-
tion into the eye [18]. However, it also disrupts cellular
processes [18, 25] and reduces tear film production [20]
and stability [31, 32]. Eliminating or reducing exposure
Fig. 2 Ocular hyperemia severity at baseline and week 12. Hyperemia
was assessed by study personnel using a scoring system ranging from
0 (no hyperemia) to 3 (severe hyperemia)
Fig. 3 Responses to the adherence question by category. Patients chose their level of confidence (ie, “not at all confident,” “somewhat confident,”
or “very confident”) in answer to the question, “How confident are you that you will use your glaucoma medication as prescribed, if your doctor
prescribed the medication?”
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to BAK in ophthalmic solutions improves tear film sta-
bility [20], reduces conjunctival hyperemia [21], and
improves dry eye symptoms [30, 33]. For example, tran-
sitioning from BAK-containing latanoprost to BAK-free
travoprost preserved with sofZia® significantly decreased
hyperemia severity and superficial punctate keratitis [28].
In the current study, transitioning from BAK-containing
latanoprost to BAK-free travoprost significantly reduced
the incidence and severity of hyperemia. The percentage
of patients with mild hyperemia was relatively unchanged
after transitioning to BAK-free travoprost; however, the
percentage of patients who reported moderate or severe
hyperemia decreased after the transition and the percent-
age of patients with no hyperemia or only trace hyperemia
increased, suggesting there was a net shift toward less se-
vere hyperemia.
Glaucoma is a progressive disorder that requires chronic
daily medication; however, up to 70 % of patients are non-
adherent to their medications within the first year [34].
Hyperemia, pain, burning, and ocular discomfort are com-
mon causes of patient nonadherence. In the current study,
most patients preferred BAK-free travoprost with PQ over
latanoprost containing BAK. This preference may be re-
lated to the low ocular discomfort reported with BAK-free
travoprost and the reduction in hyperemia severity. In-
deed, the percentage of patients who preferred BAK-free
travoprost (81.5 %) was similar to the percentage of pa-
tients who were very confident that they would adhere to
a treatment regimen that did not cause burning or sting-
ing (83.8 %). Patients reported high anticipated adherence
for their preferred treatment and for a treatment that did
not make their eyes burn or sting; a potential increase
in adherence with BAK-free travoprost compared with
BAK-preserved latanoprost may have contributed to
the increased number of patients who achieved the IOP
goal of ≤18 mmHg at week 12 compared with baseline.
Interpretation of the current results is limited by the
design of the study. Some of the reductions in ocular
hyperemia severity may be attributable to observer bias,
given the open-label nature of the study. Further, the
proportion of patients receiving generic or branded
latanoprost at screening was not assessed; potential dif-
ferences in excipients of these formulations may have
differentially influenced baseline severity of ocular
hyperemia. The suggestive nature of the questions asses-
sing confidence in treatment adherence with regard to
medication preference and burning or stinging may have
introduced bias in patient responses. Transitioning all pa-
tients to BAK-free travoprost prevented comparison with
other prostaglandin analogs and did not allow comparison
with remaining on latanoprost; however, this study was
specifically designed to evaluate therapeutic transition
among patients for which intolerability necessitated a
therapeutic change. The 12-week study duration did not
allow conclusions regarding the long-term tolerability and
efficacy of BAK-free travoprost with PQ.
Conclusions
Transitioning patients who were intolerant of latano-
prost 0.005 % to BAK-free travoprost 0.004 % reduced
IOP, improved hyperemia levels, and demonstrated few
side effects. Most patients preferred BAK-free travoprost
over latanoprost and rated themselves more likely to be
compliant with treatment.
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Table 1 Treatment-related adverse events
AE, n (%) BAK-Free Travoprost
(n = 191)
Eye irritation 7 (3.7)
Eye pruritus 6 (3.1)
Eye pain 5 (2.6)
Foreign body sensation in eyes 3 (1.6)
Ocular hyperemia 3 (1.6)
Abnormal sensation in the eye 2 (1.0)




Skin hyperpigmentation 1 (0.5)
Conjunctival edema 1 (0.5)
Dry eye 1 (0.5)
AE = adverse event; BAK = benzalkonium chloride
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